EMA Authorised: Lyfnua (gefapixant) — Merck Sharp & Dohme B.V.

View source ↗

Summary

EMA authorised Lyfnua (gefapixant) by Merck Sharp & Dohme B.V. for the treatment of chronic cough.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cough

Drugs mentioned

• Lyfnua (gefapixant)

Snippet

Status: Authorised. Therapeutic area: Cough. MAH: Merck Sharp & Dohme B.V.. Decision date: 05/12/2025